Indivisible Partners Acquires New Shares in Astrazeneca Plc $AZN

Key Points

• Indivisible Partners acquired a new stake of 13,043 shares in AstraZeneca during Q4, valued at approximately $2.29 million.
• Analyst sentiment has turned bullish with multiple recent upgrades — 12 analysts rate the stock a Buy and one a Sell, resulting in an average rating of “Moderate Buy” and an average target price of $205.33.
• AstraZeneca beat quarterly estimates with EPS $2.58 vs. $2.52 expected and revenue of $15.29 billion vs. $14.93 billion, while the shares opened at $181.36 and were trading down about 1.1%.

Indivisible Partners acquired a new stake in Astrazeneca Plc (NYSE:AZN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 13,043 shares of the company's stock, valued at approximately $2,289,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bangor Savings Bank lifted its position in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company's stock valued at $28,000 after acquiring an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new position in shares of Astrazeneca during the 4th quarter valued at $30,000. Triumph Capital Management bought a new position in shares of Astrazeneca during the 3rd quarter valued at $25,000. YANKCOM Partnership bought a new position in shares of Astrazeneca during the 4th quarter valued at $31,000. Finally, TFC Financial Management Inc. lifted its holdings in shares of Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company's stock valued at $32,000 after buying an additional 335 shares during the period. 20.35% of the stock is owned by institutional investors.

Get Astrazeneca SMS alerts:

Sign Up

Analyst Upgrades and Downgrades

AZN has been the topic of several research analyst reports. TD Cowen reissued a "buy" rating on shares of Astrazeneca in a report on Wednesday, March 18th. Barclays raised Astrazeneca from a "neutral" rating to a "buy" rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. reissued a "buy" rating on shares of Astrazeneca in a report on Thursday, April 23rd. Wall Street Zen raised Astrazeneca from a "hold" rating to a "buy" rating in a report on Saturday. Finally, UBS Group reissued a "buy" rating on shares of Astrazeneca in a report on Friday, April 10th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $205.33.

Astrazeneca Trading Down 1.1%

NYSE:AZN opened at $181.36 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a market capitalization of $281.27 billion, a price-to-earnings ratio of 27.23, a price-to-earnings-growth ratio of 1.51 and a beta of 0.26. Astrazeneca Plc has a one year low of $132.32 and a one year high of $212.71. The business has a fifty day moving average price of $195.55 and a 200-day moving average price of $180.54.

Astrazeneca (NYSE:AZN - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Sell-side analysts forecast that Astrazeneca Plc will post 10.26 EPS for the current year.

Astrazeneca Announces Dividend

The firm also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca's dividend payout ratio is presently 73.43%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.